A recent study of an experimental therapy that alters cancer patients’ own immune cells to recognize an often deadly form of leukemia has shrunk tumors and sent the cancer into remission in adults.
The Centers for Medicare & Medicaid Services announced its final decision on a coverage policy that will limit patient access to beta-amyloid positron emissiontomography imaging.
The Drug Quality and Security Act (H.R. 3204) that provides uniform, nationwide standards for both pharmacy compounding and drug tracking was enacted into law in November.
The American Autoimmune Related Diseases Association (AARDA) has created a new multimedia public service campaign with tools designed to help patients make informed decisions about newly prescribed therapies and treatments.
A new study shows that more than half of those who write prescriptions today do so electronically.
Collaborating scientists from Nationwide Children’s Hospital, Baylor Institute for Immunology Research and Mount Sinai School of Medicine have identified an important mechanism for stimulating protective immune responses following seasonal influenza vaccinations.
A computer model for predicting flu outbreaks weeks in advance has been developed by researchers at Columbia University and the National Center for Atmospheric Research.
A recent study showed that a universal flu vaccine induced levels of anti-flu antibodies 34 times higher in mice and 10 times higher in ferrets compared with a traditional vaccine.
A study conducted by researchers at the Centers for Disease Control and Prevention found that pregnant women can safely receive the meningococcal vaccine Menactra.
Researchers at Boston Children’s Hospital have identified a potent compound that activates immune responses in newborns’ white blood cells substantially better than anything previously tested, and that could make vaccines effective right after birth.
U.S. Health and Human Services Secretary Kathleen Sebelius recognized more than 900 Champions for Coverage organizations nationwide in September.
Results from a large clinical trial of Sanofi Pasteur’s Fluzone High-Dose showed that the influenza vaccine was 24.2 percent more effective against lab-confirmed flu than the traditional vaccine dose in adults 65 and older.
